Journal article icon

Journal article

Immune responses in DAA treated chronic hepatitis C patients with and without prior RG-101 dosing

Abstract:

With the introduction of DAA's, the majority of treated chronic hepatitis C patients (CHC) achieve a viral cure. The exact mechanisms by which the virus is cleared after successful therapy, is still unknown. The aim was to assess the role of the immune system and miRNA levels in acquiring a sustained virological response after DAA treatment in CHC patients with and without prior RG-101 (anti-miR-122) dosing.In this multicenter, investigator-initiated study, 29 patients with hepatitis C virus ...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed

Actions


Access Document


Files:
Publisher copy:
10.1016/j.antiviral.2017.08.016

Authors


More by this author
Institution:
University of Oxford
Division:
MSD
Department:
NDM
Sub department:
NDM Experimental Medicine
Role:
Author
More by this author
Institution:
University of Oxford
Division:
MSD
Department:
NDM
Sub department:
NDM Experimental Medicine
Role:
Author
Expand authors...
More from this funder
Funding agency for:
Klenerman, P
Grant:
U19AI082630
More from this funder
Funding agency for:
Klenerman, P
Grant:
U19AI082630
More from this funder
Funding agency for:
Klenerman, P
Grant:
U19AI082630
More from this funder
Funding agency for:
Klenerman, P
Grant:
U19AI082630
More from this funder
Funding agency for:
Klenerman, P
Grant:
U19AI082630
Expand funders...
Publisher:
Elsevier Publisher's website
Journal:
Antiviral Research Journal website
Volume:
146
Pages:
139-145
Publication date:
2017-08-24
Acceptance date:
2017-08-23
DOI:
EISSN:
1872-9096
ISSN:
0166-3542
Pmid:
28844749
Source identifiers:
725933
Language:
English
Keywords:
Pubs id:
pubs:725933
UUID:
uuid:59feb408-507e-48de-b9c5-e41d317989d8
Local pid:
pubs:725933
Deposit date:
2017-09-15

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP